Promising results in a recent outcomes report for the MAVERIC clinical trial

GenesisCare, Australia’s leading private provider of cardiac treatment services, is pleased to announce that promising results and improvement in patients’ mitral valve regurgitation are demonstrated in a recent outcomes report for the MAVERIC clinical trial. GenesisCare is currently enrolling patients to participate in this trial.

The trial is a major step forward for treating heart disease in Australia, potentially providing a new option for patients with mitral valve disease that are at high risk for open heart surgery. The commonest cause of a leaking mitral valve is congestive heart failure The world-first study explores the use of a new and less invasive, valve device using an innovative implantation technique.

The study’s 2 year outcomes report shows promising results and improvement in the patients’ mitral regurgitation. Find out more in the report.

For more information on this trial visit on our clinical trials page.

Related articles

Local cancer patients in Mandurah set to benefit from new chemotherapy service

World-class cancer treatment machine arrives at GenesisCare Bundaberg

GE Healthcare, GenesisCare Partner to Tackle Two Biggest Health Burdens Globally

Establishing partnerships inside and out for improved patient outcomes